First-in-man histotripsy of hepatic tumors: the THERESA trial, a feasibility study

References

• Bruix J, Sherman M. American association for the study of liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–1022.
   PubMed Web of Science ®Google Scholar
• Benson AB, D’Angelica MI, Abbott DE, et al. Guidelines insights: hepatobiliary cancers, version 2.2019. J Natl Compr Canc Netw. 2019;17(4):302–310.
   PubMed Web of Science ®Google Scholar
• Benson AB, Venook AP, Al-Hawary MM, et al. NCCN guidelines insights: colon cancer, version 2.2018. J Natl Compr Canc Netw. 2018;16(4):359–369.
   PubMed Web of Science ®Google Scholar
• Shah MH, Goldner WS, Halfdanarson TR, et al. NCCN guidelines insights: neuroendocrine and adrenal tumors, version 2.2018. J Natl Compr Canc Netw. 2018;16(6):693–702.
   PubMed Web of Science ®Google Scholar
• Livraghi T, Solbiati L, Meloni MF, et al. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology. 2003;226(2):441–451.
   PubMed Web of Science ®Google Scholar
• Livraghi T, Meloni F, Solbiati L. et al. Collaborative Italian group using as. Complications of microwave ablation for liver tumors: results of a multicenter study. Cardiovasc Intervent Radiol. 2012;35(4):868–874.
   PubMed Web of Science ®Google Scholar
• Liang P, Wang Y, Yu X, et al. Malignant liver tumors: treatment with percutaneous microwave ablation–complications among cohort of 1136 patients. Radiology. 2009;251(3):933–940.
   PubMed Web of Science ®Google Scholar
• Sapisochin G, Barry A, Doherty M, et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol. 2017;67(1):92–99.
   PubMed Web of Science ®Google Scholar
• Shady W, Petre EN, Gonen M, et al. Percutaneous radiofrequency ablation of colorectal cancer liver metastases: factors affecting outcomes–a 10-year experience at a single center. Radiology. 2016;278(2):601–611.
   PubMed Web of Science ®Google Scholar
• Livraghi T, Meloni F, Di Stasi M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology. 2007;47(1):82–89.
   Web of Science ®Google Scholar
• Liang P, Yu J, Yu XL, et al. Percutaneous cooled-tip microwave ablation under ultrasound guidance for primary liver cancer: a multicentre analysis of 1363 treatment-naive lesions in 1007 patients in China. Gut. 2012;61(7):1100–1101.
   PubMed Web of Science ®Google Scholar
• Xu Z, Hall TL, Vlaisavljevich E, et al. Histotripsy: the first noninvasive, non-ionizing, non-thermal ablation technique based on ultrasound. Int J Hyperthermia. 2021;38(1):561–575.
   PubMed Web of Science ®Google Scholar
• Smolock AR, Cristescu MM, Vlaisavljevich E, et al. Robotically assisted sonic therapy as a non-invasive nonthermal ablation modality: proof of concept in a porcine liver model. Radiology. 2018;287(2):485–493.
   PubMed Web of Science ®Google Scholar
• Worlikar T, Vlaisavljevich E, Gerhardson T, et al. Histotripsy for non-invasive ablation of hepatocellular carcinoma (HCC) tumor in a subcutaneous xenograft murine model. Annu Int Conf IEEE Eng Med Biol Soc. 2018;2018:6064–6067.
   PubMedGoogle Scholar
• Vlaisavljevich E, Owens G, Lundt J, et al. Noninvasive liver ablation using histotripsy: preclinical safety study in an in vivo porcine model. Ultrasound Med Biol. 2017;43(6):1237–1251.
   PubMed Web of Science ®Google Scholar
• Longo KC, Knott EA, Watson RF, et al. Robotically Assisted Sonic Therapy (RAST) for noninvasive hepatic ablation in a porcine model: Mitigation of body wall damage with a modified pulse sequence. Cardiovasc Intervent Radiol. 2019;42(7):1016–1023.
   PubMed Web of Science ®Google Scholar
• Coenegrachts K. Magnetic resonance imaging of the liver: new imaging strategies for evaluating focal liver lesions. World J Radiol. 2009;1(1):72–85.
   PubMedGoogle Scholar
• Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. May 28, 2009 (v4.03: June 14, 2010.
   Google Scholar
• Ahmed M, Solbiati L, Brace CL, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria–a 10-year update. Radiology. 2014;273(1):241–260.
   PubMed Web of Science ®Google Scholar
• Arraras JI, Arias F, Tejedor M, et al. The EORTC QLQ-C30 (version 3.0) quality of life questionnaire: validation study for Spain with head and neck cancer patients. Psychooncology. 2002;11(3):249–256.
   PubMed Web of Science ®Google Scholar
• Tacher V, Lin M, Duran R, et al. Comparison of existing response criteria in patients with hepatocellular carcinoma treated with transarterial chemoembolization using a 3D quantitative approach. Radiology. 2016;278(1):275–284.
   PubMed Web of Science ®Google Scholar
• Chapiro J, Wood LD, Lin M, et al. Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis. Radiology. 2014;273(3):746–758.
   PubMed Web of Science ®Google Scholar
• Duran R, Chapiro J, Frangakis C, et al. Uveal melanoma metastatic to the liver: the role of quantitative volumetric Contrast-Enhanced MR imaging in the assessment of early tumor response after transarterial chemoembolization. Transl Oncol. 2014;7(4):447–45523.
   PubMed Web of Science ®Google Scholar
• Sahu S, Schernthaner R, Ardon R, et al. Imaging biomarkers of tumor response in neuroendocrine liver metastases treated with transarterial chemoembolization: can enhancing tumor burden of the whole liver help predict patient survival? Radiology. 2017;283(3):883–894.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Duran R, Bai W, et al. Which criteria applied in multi-phasic CT can predict early tumor response in patients with hepatocellular carcinoma treated using conventional TACE: RECIST, mRECIST, EASL or qEASL? Cardiovasc Intervent Radiol. 2018;41(3):433–442.
   PubMed Web of Science ®Google Scholar
• Schuster TG, Wei JT, Hendlin K, et al. Histotripsy treatment of benign prostatic enlargement using the Vortx Rx system: initial human safety and efficacy outcomes. Urology. 2018;114:184–187.
   PubMed Web of Science ®Google Scholar
• Qu S, Worlikar T, Felsted AE, et al. Non-thermal histotripsy tumor ablation promotes abscopal immune responses that enhance cancer immunotherapy. J Immunother Cancer. 2020;8(1):e000200.
   PubMed Web of Science ®Google Scholar
• Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol. 1953;26(305):234–241.
   PubMed Web of Science ®Google Scholar
• Ngwa W, Irabor OC, Schoenfeld JD, et al. Using immunotherapy to boost the abscopal effect. Nat Rev Cancer. 2018;18(5):313–322.
   PubMed Web of Science ®Google Scholar
• Sugimoto K, Kakimi K, Takeuchi H, et al. Irreversible electroporation versus radiofrequency ablation: comparison of systemic immune responses in patients with hepatocellular carcinoma. J Vasc Interv Radiol. 2019;30(6):845–853 e6.
   PubMed Web of Science ®Google Scholar
• Pandit H, Hong YK, Li Y, et al. Evaluating the regulatory immunomodulation effect of irreversible electroporation (IRE) in pancreatic adenocarcinoma. Ann Surg Oncol. 2019;26(3):800–806.
   PubMed Web of Science ®Google Scholar
• Hendricks-Wenger A, Sereno J, Gannon J, et al. Histotripsy ablation alters the tumor microenvironment and promotes immune system activation in a subcutaneous model of pancreatic cancer. IEEE Trans Ultrason Ferroelect Freq Contr. 2021;68(9):2987–3000.
   PubMed Web of Science ®Google Scholar
• Worlikar T, Zhang M, Ganguly A, et al. Impact of histotripsy on development of intrahepatic metastases in a rodent liver tumor model. Cancers. 2022;14(7):1612.
   PubMed Web of Science ®Google Scholar